You are here

Clinical Trials

Durvalumab/tremelimumab combo fails to improve PFS compared to chemotherapy
NKTR-181 is a first-in-class investigational opioid to treat chronic pain
Paratek is planning to submit an application in the first quarter of 2018
Patients lived 7.9 months longer than those receiving lenalidomide and dexamethasone alone
Monoclonal antibody is administered once weekly via subcutaneous injection
Immune response is noninferior to that of Zostavax
Treatment extends PFS by more than one year in late-stage study
Company plans FDA submission by mid-year
Analyst gives treatment 50/50 chance of coming to market
After 56 weeks of treatment with Saxenda, 91.7% of early responders maintained or lost additional weight
Drug demonstrated clinically meaningful results with infrequent subcutaneous administration
Treatment reduces mortality risk in patients with advanced disease